morpholine has been researched along with Disease Models, Animal in 5 studies
*Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonham, CA; Chenevert, TL; Heist, K; Jang, Y; Luker, GD; McDonald, L; Palagama, DSW; Ross, BD; Van Dort, ME; Zhang, EZ | 1 |
| Katselou, MG; Kourounakis, AP; Matralis, AN | 1 |
| Aljayyoussi, G; Amewu, RK; Angulo-Barturén, I; Bazaga, SF; Belén, M; Biagini, GA; Campo, B; Charman, SA; Chen, G; Davies, J; Martínez, MS; Nixon, GL; O' Neill, PM; Roberts, NL; Ryan, E; Sabbani, S; Shackleford, DM; Sharma, R; Shore, ER; Stocks, PA; Ward, SA | 1 |
| Kourounakis, AP; Ladopoulou, EM; Matralis, AN; Nikitakis, A | 1 |
| Bara, T; Clader, JW; Favreau, L; Greenlee, WJ; Hyde, LA; Josien, H; Nomeir, AA; Parker, EM; Rajagopalan, M; Song, L; Zhang, L; Zhang, Q | 1 |
5 other study(ies) available for morpholine and Disease Models, Animal
| Article | Year |
|---|---|
Structural effects of morpholine replacement in ZSTK474 on Class I PI3K isoform inhibition: Development of novel MEK/PI3K bifunctional inhibitors.
Topics: Animals; Binding Sites; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Molecular Docking Simulation; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Primary Myelofibrosis; Protein Isoforms; Structure-Activity Relationship; Triazines | 2022 |
Developing potential agents against atherosclerosis: Design, synthesis and pharmacological evaluation of novel dual inhibitors of oxidative stress and Squalene Synthase activity.
Topics: Animals; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hypolipidemic Agents; Male; Mice; Mice, Hairless; Molecular Structure; Morpholines; Oxidative Stress; Rats; Structure-Activity Relationship; Thiazines | 2017 |
Synthesis and profiling of benzylmorpholine 1,2,4,5-tetraoxane analogue N205: Towards tetraoxane scaffolds with potential for single dose cure of malaria.
Topics: Administration, Oral; Animals; Antimalarials; Disease Models, Animal; Drug Stability; Humans; Inhibitory Concentration 50; Malaria; Mice; Morpholines; Plasmodium falciparum; Rats; Tetraoxanes | 2018 |
Antihyperlipidemic morpholine derivatives with antioxidant activity: An investigation of the aromatic substitution.
Topics: Animals; Antioxidants; Binding Sites; Catalytic Domain; Disease Models, Animal; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypolipidemic Agents; Inhibitory Concentration 50; Microsomes, Liver; Molecular Docking Simulation; Morpholines; Rats | 2015 |
Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability.
Topics: Administration, Oral; Amyloid Precursor Protein Secretases; Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Disease Models, Animal; Enzyme Inhibitors; Humans; Mice; Mice, Transgenic; Morpholines; Rats; Sulfonamides | 2009 |